Lopinavir molecular structure

Lopinavir

Also known as: Kaletra and Aluvia components, Lopimune, Lopimac (always co-formulated with ritonavir)

CAS Number: 192725-17-0

HIV Protease Inhibitor

Pharmacopeia Standards

USPIPEPWHO

Mechanism of Action

Lopinavir is a peptidomimetic that binds the C2-symmetric active site of HIV-1 protease and blocks hydrolysis of gag and gag-pol polyprotein precursors. The resulting virions retain uncleaved structural and enzymatic proteins and are non-infectious. Lopinavir is extensively metabolised by CYP3A4, which is why it is invariably co-formulated with low-dose ritonavir as a pharmacokinetic booster.

Technical Specifications

Generic / INN NameLopinavir
CAS Registry Number192725-17-0
Molecular FormulaC37H48N4O5
Molecular Weight628.80 g/mol g/mol
Typical PurityNot less than 98.0% on anhydrous basis; chiral purity not less than 99.0%
Storage ConditionsStore below 25 degrees C in tightly closed containers protected from light and moisture; desiccant recommended.
Shelf Life36 months from date of manufacture in original sealed packing
CategoryAntiretrovirals (HIV)

Specifications are indicative and intended for sourcing reference only. Always confirm against the supplier's Certificate of Analysis and the applicable pharmacopeial monograph before issuing a purchase specification.

Typical Applications

Bulk API exclusively for lopinavir and ritonavir co-formulated products, including heat-stable film-coated tablets, paediatric oral pellets and granules, and oral solutions used in second-line and paediatric ARV therapy.

Manufacturers (0+)

View all →
No manufacturers listed yet. Register your company to appear here.